The trading price of AbCellera Biologics Inc (NASDAQ:ABCL) floating higher at last check on Wednesday, April 24, closing at $4.15, 4.53% higher than its previous close.
In examining the 52-week price action we see that the stock hit a 52-week high of $8.05 and a 52-week low of $3.79. Over the past month, the stock has lost -9.39% in value.
AbCellera Biologics Inc, whose market valuation is $1.22 billion at the time of this writing. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -0.17 per share this quarter, however they have predicted annual earnings per share of -0.65 for current year and -0.7 for next year.
Analysts have forecast the company to bring in revenue of 10.84M for the current quarter, with the likely lows of 8.9M and highs of 18.29M. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 47.55M.
On the technical side, indicators suggest ABCL has a 100% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
A quick review shows that ABCL’s price is currently -2.92% off the SMA20 and -11.07% off the SMA50. The RSI metric on the 14-day chart is currently showing 43.59, and weekly volatility stands at 5.43%. When measured over the past 30 days, the indicator reaches 5.02%. AbCellera Biologics Inc (NASDAQ:ABCL)’s beta value is currently sitting at 0.39, while the Average True Range indicator is currently displaying 0.22.
To see how AbCellera Biologics Inc stock has been performing today in comparison to its peers in the industry, here are the numbers: ABCL stock’s performance was 4.53% at last check in today’s session, and -42.12% in the past year.
An evaluation of the daily trading volume of AbCellera Biologics Inc (NASDAQ:ABCL) indicates that the 3-month average is 1.34 million.
Currently, records show that 290.82 million of the company’s shares remain outstanding. The insiders hold 29.92% of outstanding shares, whereas institutions hold 38.40%. However, since the stock’s price has seen -27.32% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
